Different parameters increase the risk of severe disease after infection with SARS-CoV-2. The indicators are listed in the COVID-19 risk group regulation.
These include, for example:
-- chronic heart disease (e.g., ischemic heart disease, congestive heart failure),
-- active cancers,
-- diseases treated with permanent and relevant immunosuppression (e.g., transplants, permanent cortisone therapy, HIV),
-- chronic kidney disease (e.g., renal insufficiency, renal replacement therapy).
-- chronic liver disease with organ remodeling and decompensated cirrhosis,
-- marked obesity grade III with a BMI over 40,
-- diabetes mellitus or
-- arterial hypertension with existing end-organ damage.
Vaccination schedule for at-risk individuals
For optimal protection against severe disease progression and Long COVID, at-risk individuals are advised to refresh their vaccination earlier.[source: Vaccination schedule for Corona vaccination]
COVID-19 medications as an additional safety net.
COVID-19 medications do not replace vaccination. They are an additional safety net especially for people at risk. This is especially true for older people and those with pre-existing conditions. If taken in time, COVID-19 medications can prevent serious illness and thus hospitalization.
It is important that COVID-19 medications are taken as soon as possible after a positive test result. Get advice: from your doctor or at your pharmacy.
[More on COVID-19 medications here.]
Protection of the at-risk group in the workplace
A COVID-19 risk certificate confirms a possible increased risk of severe disease progression and is issued by the:respective treating physician:in. This results in a claim for additional protective measures in the workplace, such as workplace redesign or home office. If this is not possible, a temporary leave of absence can be taken. In addition, protection against dismissal for persons with COVID-19 risk attestation has been enshrined in law for the period of the current regulation. The current rule is effective for the time being until December 31, 2022.